Genomate®

Name: [redacted]
DOB: [redacted]/80
Sex: Female

Report Date: 08/03/23
Report ID: 605767
Patient ID: [redacted]

Tumor Type: Breast Invasive Carcinoma

High Genomate Drug Score (GDS)

I. Drugs Approved in Patient's Tumor Type

DRUG	GDS
TRASTUZUMAB DERUXTECAN + *7…*	10387
PEMBROLIZUMAB	6548
EVEROLIMUS	5179
ALPELISIB	4737
RIBOCICLIB + *2 CDK4 inhibitors*	3713
ATEZOLIZUMAB	3034
TALAZOPARIB + *1 PARP1 inhibitor*	2766

+ 10 drugs

II. Drugs Approved in Other Tumor Type

DRUG	GDS
COPANLISIB	3816
AFATINIB + *1 ERBB2 inhibitor*	3749
SIROLIMUS + *2 MTOR inhibitors*	3633
RUCAPARIB + *1 PARP1 inhibitor*	2714
NIVOLUMAB	2482
ASPIRIN	1477
AVELUMAB + *1 PD-L1 inhibitor*	1433

+ 6 drugs

III. Drugs in Clinical Trials

DRUG	GDS
CAPIVASERTIB + *12 AKT1 inhibitors*	6377
DACTOLISIB + *27 PIK3CA inhibitors*	6267
PYROTINIB + *17 ERBB2 inhibitors*	6249
ELGEMTUMAB + *9 ERBB3 inhibitors*	3546
PAMIPARIB + *17 PARP1 inhibitors*	2647
DINACICLIB	2602
ONATASERTIB + *8 MTOR inhibitors*	2234

+ 112 drugs

Intermediate Genomate Drug Score (GDS)

I. Drugs Approved in Patient's Tumor Type

DRUG	GDS
ENTRECTINIB	765
ANASTROZOLE	89
BEVACIZUMAB	80
SACITUZUMAB GOVITECAN	7

II. Drugs Approved in Other Tumor Type

DRUG	GDS
RALOXIFENE HYDROCHLORIDE	948
CERITINIB	428
CEMIPLIMAB + *1 PD-1 inhibitor*	294
DASATINIB	85

+ 60 drugs

III. Drugs in Clinical Trials

DRUG	GDS
DALPICICLIB	832
TIRAGOLUMAB	650
BINTRAFUSP ALFA + *3 PD-L1 inhibitors*	550
MK-8776 + *4 CHEK1 inhibitors*	386

+ 98 drugs

Low Genomate Drug Score (GDS)

I. Drugs Approved in Patient's Tumor Type

DRUG	GDS
TAMOXIFEN	-2940
LETROZOLE	-1784
FULVESTRANT	-1726
EXEMESTANE	-1192

II. Drugs Approved in Other Tumor Type

DRUG	GDS
PANITUMUMAB + *8 EGFR inhibitors*	-6185
BAZEDOXIFENE	-2096
CRIZOTINIB + *3 MET inhibitors*	-2002
VEMURAFENIB	-1422

+ 21 drugs

III. Drugs in Clinical Trials

DRUG	GDS
BIBX 1382 + *13 EGFR inhibitors*	-3634
SRN-927 + *5 ESR1 inhibitors*	-2096
Anthracycline	-1420
CI-1040 + *15 MAP2K1 inhibitors*	-1395

+ 57 drugs

Molecular Profile Analysis

Test Information

Test Type	Report Date	Panel
IHC	03/24/23	
IHC	01/01/22	
IHC	01/01/23	
NGS	08/03/23	FoundationOne
IHC	07/01/20	
FISH	01/01/22	

Molecular Biomarkers

Molecular Biomarkers	Genomate Biomarker Score
PIK3CA-H1047R	1391
ERBB2 overexpression	1185
ERBB2 amplification	1016
ESR1 overexpression	879
PD-L1 overexpression	630
ROS1 translocation	370
RB1 gene loss	100
BRCA1-S768R	82
MYC amplification	70
TP53-G266R	64
PGR overexpression	63
NBN amplification	9
STAG2-A570V	4
FANCA-V1180M	3
RAD21 amplification	2
ERBB4-T209S	1
PARP2-L509F	0
EPHA3-E408G	0
SETD2-D868G	0
ROS1-P151L	-5

Target Genes

Target Gene	Positively Associated Biomarkers	Negatively Associated Biomarkers	Genomate Target Score

Target Gene	Positively Associated Biomarkers	Negatively Associated Biomarkers	Genomate Target Score
ERBB2	ERBB2 overexpression ERBB2 amplification	PIK3CA-H1047R	3657
PIK3CA	PIK3CA-H1047R ESR1 overexpression	MYC amplification	2422
MTOR	PIK3CA-H1047R ESR1 overexpression	MYC amplification	2234
AKT1	ESR1 overexpression PIK3CA-H1047R	MYC amplification	2204
CTNNB1	PIK3CA-H1047R	-	1391
AKT3	PIK3CA-H1047R	-	1391
AKT2	PIK3CA-H1047R	-	1391
PARP1	FANCA-V1180M STAG2-A570V ERBB2 overexpression BRCA1-S768R	NBN amplification	1376
PARP2	ERBB2 overexpression	-	1186
ERBB3	ERBB2 overexpression	-	1185
CDK12	MYC amplification ERBB2 amplification	- -	1088
PTPN11	ERBB2 amplification	-	1017
EIF4A1	ERBB2 amplification	-	1017
CDK4	TP53-G266R ESR1 overexpression	RB1 gene loss	830
PD-L1	STAG2-A570V PD-L1 overexpression BRCA1-S768R	ROS1 translocation MYC amplification	550
CHEK1	BRCA1-S768R RB1 gene loss MYC amplification TP53-G266R	- - - -	320
PD-1	BRCA1-S768R PD-L1 overexpression	MYC amplification ROS1 translocation	293
PLK1	RB1 gene loss TP53-G266R	- -	166
CDK2	RB1 gene loss TP53-G266R	- -	165
CDK1	MYC amplification TP53-G266R	- -	138
AURKA	RB1 gene loss	-	102
BRD4	MYC amplification	-	74
ATR	STAG2-A570V TP53-G266R	- -	71
PRKDC	TP53-G266R STAG2-A570V	- -	70
WEE1	TP53-G266R	-	69
CDK9	TP53-G266R	-	65
RARG	TP53-G266R	-	65

Target Gene	Positively Associated Biomarkers	Negatively Associated Biomarkers	Genomate Target Score
AURKB	TP53-G266R	-	65
ERBB4	ERBB4-T209S	-	45
STAG1	STAG2-A570V	-	8
XRCC5	STAG2-A570V	-	5
BRCA1	STAG2-A570V	-	5
RAD51	STAG2-A570V	-	5
COX2	ERBB4-T209S	-	2
PIK3CB	SETD2-D868G	-	1
ROS1	ROS1 translocation	ERBB2 overexpression	-93
MET	-	PIK3CA-H1047R	-1391
MAP2K1	-	PIK3CA-H1047R	-1391
ESR1	ESR1 overexpression	MYC amplification	-2096
		ERBB2 overexpression	
		ERBB2 amplification	
		PIK3CA-H1047R	
EGFR	-	ERBB2 overexpression	-3634
	-	PIK3CA-H1047R	
	-	ERBB2 amplification	

Additional Therapy Options

Genomate Drug Scores (GDS): High GDS | Intermediate GDS | Low GDS

Drug Categories: Category I: Drugs Approved in Patient's Tumor Type | Category II: Drugs Approved in Other Tumor Type | Category III: Drugs in Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
TRASTUZUMAB DERUXTECAN	10387	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	Approved - This Tumor Type
TRASTUZUMAB	8847	ERBB2	ERBB2 amplification ERBB2 overexpression	PIK3CA-H1047R	Approved - This Tumor Type
TRASTUZUMAB EMTANSINE	8520	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	Approved - This Tumor Type
PERTUZUMAB	6923	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	Approved - This Tumor Type
PEMBROLIZUMAB	6548	PD-1	PD-L1 overexpression	-	Approved - This Tumor Type
TUCATINIB	6486	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	Approved - This Tumor Type
CAPIVASERTIB	6377	AKT1 AKT2 AKT3	PIK3CA-H1047R	- - -	In Clinical Trials
DACTOLISIB	6267	PIK3CB MTOR PIK3CA	PIK3CA-H1047R	- - -	In Clinical Trials
PYROTINIB	6249	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	In Clinical Trials
MARGETUXIMAB	6090	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	Approved - This Tumor Type
OMIPALISIB	6051	PIK3CB MTOR PIK3CA	PIK3CA-H1047R	- - -	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
DS-7423	6048	PIK3CB MTOR PIK3CA	PIK3CA-H1047R	- - -	In Clinical Trials
TRASTUZUMAB DUOCARMAZINE	6022	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	In Clinical Trials
POZIOTINIB	5984	ERBB2 ERBB4	ERBB2 amplification ERBB2 overexpression	- -	In Clinical Trials
ZENOCUTUZUMAB	5966	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	In Clinical Trials
DISITAMAB VEDOTIN	5938	ERBB2	ERBB2 amplification ERBB2 overexpression	- -	In Clinical Trials
TASELISIB	5906	PIK3CA	ESR1 overexpression ERBB2 amplification PIK3CA-H1047R	- - -	In Clinical Trials
EVEROLIMUS	5179	MTOR	ESR1 overexpression PIK3CA-H1047R	MYC amplification	Approved - This Tumor Type
ZANIDATAMAB	5003	ERBB2	ERBB2 overexpression	-	In Clinical Trials
IPATASERTIB	4987	AKT1 AKT2 AKT3	- - -	- - -	In Clinical Trials
AFURESERTIB	4986	AKT1 AKT3 AKT2	- - -	- - -	In Clinical Trials
TRICIRIBINE	4986	AKT1 AKT2	PIK3CA-H1047R	- -	In Clinical Trials
ERTUMAXOMAB	4928	ERBB2	ERBB2 overexpression	-	In Clinical Trials
ARX788	4923	ERBB2	ERBB2 overexpression	-	In Clinical Trials
HER2-CD28 CAR T-cells	4920	ERBB2	ERBB2 overexpression	-	In Clinical Trials
MM-302	4845	ERBB2	ERBB2 overexpression	-	In Clinical Trials
ALPELISIB	4737	PIK3CA	ESR1 overexpression PIK3CA-H1047R	- -	Approved - This Tumor Type
BMS-690514	4727	ERBB2 ERBB4	ERBB2 amplification	- -	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
LAPATINIB	4720	AKT1 EGFR ERBB2 ERBB4	ERBB4-T209S ERBB2 amplification ERBB2 overexpression	PIK3CA-H1047R	Approved - This Tumor Type
APITOLISIB	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
GEDATOLISIB	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
PWT33597	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
SF1126	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
PF-04691502	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
VOXTALISIB	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
BGT226	4657	PIK3CB MTOR PIK3CA	- - -	- - -	In Clinical Trials
PANULISIB	4655	MTOR PIK3CA	- -	- -	In Clinical Trials
PKI179	4655	MTOR PIK3CA	- -	- -	In Clinical Trials
VS-5584	4655	MTOR PIK3CA	- -	- -	In Clinical Trials
PI-103	4655	MTOR PIK3CA	- -	- -	In Clinical Trials
CH 5132799	3877	PIK3CB PIK3CA	PIK3CA-H1047R	- -	In Clinical Trials
INAVOLISIB	3822	PIK3CA	PIK3CA-H1047R	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
PICTILISIB	3816	PIK3CB PIK3CA	PIK3CA-H1047R	- -	In Clinical Trials
PAXALISIB	3816	PIK3CA	PIK3CA-H1047R	-	In Clinical Trials
COPANLISIB	3816	PIK3CB PIK3CA	PIK3CA-H1047R	- -	Approved - Other Tumor Type
PILARALISIB	3815	PIK3CB PIK3CA	PIK3CA-H1047R	- -	In Clinical Trials
SAMOTOLISIB	3813	PIK3CA	PIK3CA-H1047R	-	In Clinical Trials
AFATINIB	3749	EGFR ERBB2 ERBB4 ERBB3	ERBB4-T209S ERBB2 amplification ERBB2 overexpression	- - - -	Approved - Other Tumor Type
RIBOCICLIB	3713	CDK4	PGR overexpression ESR1 overexpression	RB1 gene loss	Approved - This Tumor Type
BMS-599626	3702	ERBB2 ERBB4	- -	- -	In Clinical Trials
MUBRITINIB	3657	ERBB2	-	-	In Clinical Trials
MDX-210	3657	ERBB2	-	-	In Clinical Trials
VARLITINIB	3657	ERBB2	-	-	In Clinical Trials
CP-724714	3657	ERBB2	-	-	In Clinical Trials
SIROLIMUS	3633	MTOR	PIK3CA-H1047R	-	Approved - Other Tumor Type
METFORMIN	3630	MTOR	PIK3CA-H1047R	-	Approved - Other Tumor Type
TEMSIROLIMUS	3626	MTOR	PIK3CA-H1047R	-	Approved - Other Tumor Type
MK2206	3603	AKT1	PIK3CA-H1047R	-	In Clinical Trials
ELGEMTUMAB	3546	ERBB3	ERBB2 amplification ERBB2 overexpression	- -	In Clinical Trials
ATEZOLIZUMAB	3034	PD-L1	PD-L1 overexpression	-	Approved - This Tumor Type
NERATINIB	2832	EGFR ERBB2 ERBB4 ERBB3	ERBB2 amplification ERBB2 overexpression	PIK3CA-H1047R	Approved - This Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
TALAZOPARIB	2766	PARP1 PARP2	BRCA1-S768R	- -	Approved - This Tumor Type
RUCAPARIB	2714	PARP1 PARP2	STAG2-A570V BRCA1-S768R	- -	Approved - Other Tumor Type
NIRAPARIB	2711	PARP2 PARP1	BRCA1-S768R	- -	Approved - Other Tumor Type
PAMIPARIB	2647	PARP2 PARP1	BRCA1-S768R	- -	In Clinical Trials
STENOPARIB	2645	PARP2 PARP1	BRCA1-S768R	- -	In Clinical Trials
VELIPARIB	2611	PARP1 PARP2	STAG2-A570V BRCA1-S768R	NBN amplification	In Clinical Trials
DINACICLIB	2602	CDK9 CDK1 CDK2 CDK12	MYC amplification ERBB2 amplification	- - - -	In Clinical Trials
RP12146	2562	PARP1 PARP2	- -	- -	In Clinical Trials
AZD 2461	2562	PARP1 PARP2	- -	- -	In Clinical Trials
E7016	2562	PARP1 PARP2	- -	- -	In Clinical Trials
AMXI-5001	2562	PARP1 PARP2	- -	- -	In Clinical Trials
ABT767	2562	PARP1 PARP2	- -	- -	In Clinical Trials
SENAPARIB	2562	PARP2 PARP1	- -	- -	In Clinical Trials
SC10914	2562	PARP1 PARP2	- -	- -	In Clinical Trials
FIMEPINOSTAT	2533	PIK3CB PIK3CA	MYC amplification	- -	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
OLAPARIB	2525	PARP2 PARP1	- - - -	NBN amplification STAG2-A570V BRCA1-S768R FANCA-V1180M	Approved - This Tumor Type
NIVOLUMAB	2482	PD-1	BRCA1-S768R PD-L1 overexpression	- -	Approved - Other Tumor Type
ZSTK474	2423	PIK3CB PIK3CA	- -	- -	In Clinical Trials
SONOLISIB	2423	PIK3CB PIK3CA	- -	- -	In Clinical Trials
MLN1117	2422	PIK3CA	-	-	In Clinical Trials
GSK1059615	2422	PIK3CA	-	-	In Clinical Trials
WX 037	2422	PIK3CA	-	-	In Clinical Trials
MM-111	2375	ERBB3	ERBB2 overexpression	-	In Clinical Trials
ABEMACICLIB	2339	CDK4	ESR1 overexpression	-	Approved - This Tumor Type
ONATASERTIB	2234	MTOR	-	-	In Clinical Trials
GDC 0349	2234	MTOR	-	-	In Clinical Trials
CC-115	2234	MTOR	-	-	In Clinical Trials
RES 529	2234	MTOR	-	-	In Clinical Trials
VISTUSERTIB	2234	MTOR	-	-	In Clinical Trials
Sapanisertib	2234	MTOR	-	-	In Clinical Trials
OSI-027	2234	MTOR	-	-	In Clinical Trials
AZD8055	2234	MTOR	-	-	In Clinical Trials
RIDAFOROLIMUS	2234	MTOR	-	-	In Clinical Trials
MIRANSERTIB	2204	AKT1	-	-	In Clinical Trials
AT13148	2204	AKT1	-	-	In Clinical Trials
GSK690693	2204	AKT1	-	-	In Clinical Trials
MSC 2363318A	2204	AKT1	-	-	In Clinical Trials
SR13668	2204	AKT1	-	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
GSK2141795	2204	AKT1	-	-	In Clinical Trials
DANUSERTIB	2204	AKT1	-	-	In Clinical Trials
BAY1125976	2204	AKT1	-	-	In Clinical Trials
zotatifin	2038	EIF4A1	ERBB2 amplification	-	In Clinical Trials
ASPIRIN	1477	COX2	PIK3CA-H1047R	-	Approved - Other Tumor Type
FUZULOPARIB	1462	PARP1	BRCA1-S768R	-	In Clinical Trials
AVELUMAB	1433	PD-L1	PD-L1 overexpression	-	Approved - Other Tumor Type
IDELALISIB	1410	-	PIK3CA-H1047R	-	Approved - Other Tumor Type
E7386	1391	CTNNB1	-	-	In Clinical Trials
PERIFOSINE	1391	-	PIK3CA-H1047R	-	In Clinical Trials
PRI-724	1391	CTNNB1	-	-	In Clinical Trials
CEP-9722	1376	PARP1	-	-	In Clinical Trials
INIPARIB	1376	PARP1	-	-	In Clinical Trials
AZD5305	1376	PARP1	-	-	In Clinical Trials
INO-1001	1376	PARP1	-	-	In Clinical Trials
NMS-03305293	1376	PARP1	-	-	In Clinical Trials
Amelparib	1376	PARP1	-	-	In Clinical Trials
Venadaparib	1376	PARP1	-	-	In Clinical Trials
PALBOCICLIB	1262	CDK4	ESR1 overexpression	PIK3CA-H1047R RB1 gene loss	Approved - This Tumor Type
CANERTINIB	1254	EGFR ERBB2 ERBB4 ERBB3	- - - -	- - - -	In Clinical Trials
DACOMITINIB	1254	EGFR ERBB2 ERBB4 ERBB3	- - - -	- - - -	Approved - Other Tumor Type
DURVALUMAB	1249	PD-L1	PD-L1 overexpression	-	Approved - Other Tumor Type
NK-92/5.28.z	1236	-	ERBB2 overexpression	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
HER2-pulsed DC1 vaccine	1236	-	ERBB2 overexpression	-	In Clinical Trials
XMT-1522	1234	-	ERBB2 overexpression	-	In Clinical Trials
TrasGEX	1215	-	ERBB2 overexpression	-	In Clinical Trials
ADXS31-164	1199	-	ERBB2 overexpression	-	In Clinical Trials
RONICICLIB	1198	CDK9 CDK2 CDK1 CDK4	- - - -	- - - -	In Clinical Trials
RGB-286638	1198	CDK9 CDK2 CDK1 CDK4	- - - -	- - - -	In Clinical Trials
RIVICICLIB	1198	CDK9 CDK1 CDK2 CDK4	- - - -	- - - -	In Clinical Trials
FS102	1191	-	ERBB2 overexpression	-	In Clinical Trials
ZW49	1190	-	ERBB2 overexpression	-	In Clinical Trials
MVA-BN-HER2	1188	-	ERBB2 overexpression	-	In Clinical Trials
MM-141	1185	ERBB3	-	-	In Clinical Trials
GSK2849330	1185	ERBB3	-	-	In Clinical Trials
KTN3379	1185	ERBB3	-	-	In Clinical Trials
REGN1400	1185	ERBB3	-	-	In Clinical Trials
AV 203	1185	ERBB3	-	-	In Clinical Trials
PATRITUMAB	1185	ERBB3	-	-	In Clinical Trials
LUMRETUZUMAB	1185	ERBB3	-	-	In Clinical Trials
SERIBANTUMAB	1185	ERBB3	-	-	In Clinical Trials
ALVOCIDIB	1133	CDK1 CDK2 CDK4	- - -	- - -	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
MILCICLIB	1133	CDK1 CDK2 CDK4	- - -	- - -	In Clinical Trials
EPERTINIB	1093	EGFR ERBB2	ERBB2 amplification	- -	In Clinical Trials
BUPARLISIB	1087	PIK3CB PIK3CA	TP53-G266R	PIK3CA-H1047R	In Clinical Trials
TORIPALIMAB	1064	PD-1	PD-L1 overexpression	-	In Clinical Trials
SINTILIMAB	1020	PD-1	PD-L1 overexpression	-	In Clinical Trials
JAB-3068	1017	PTPN11	-	-	In Clinical Trials
RMC 4630	1017	PTPN11	-	-	In Clinical Trials
TNO155	1017	PTPN11	-	-	In Clinical Trials
RALOXIFENE HYDROCHLORIDE	948	-	ESR1 overexpression	-	Approved - Other Tumor Type
DALPICICLIB	832	CDK4	-	-	In Clinical Trials
ENTRECTINIB	765	ROS1	ROS1 translocation	-	Approved - This Tumor Type
TIRAGOLUMAB	650	-	PD-L1 overexpression	-	In Clinical Trials
BINTRAFUSP ALFA	550	PD-L1	-	-	In Clinical Trials
MDX-1105	550	PD-L1	-	-	In Clinical Trials
PACMILIMAB	550	PD-L1	-	-	In Clinical Trials
SUGEMALIMAB	550	PD-L1	-	-	In Clinical Trials
CERITINIB	428	ROS1	ROS1 translocation	-	Approved - Other Tumor Type
MK-8776	386	CHEK1	TP53-G266R	-	In Clinical Trials
AZD5438	367	CDK9 CDK1 CDK2	- - -	- - -	In Clinical Trials
AT 7519	367	CDK9 CDK1 CDK2	- - -	- - -	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
ZOTIRACICLIB	367	CDK9 CDK2 CDK1	- - -	- - -	In Clinical Trials
TAE684	326	ROS1	ROS1 translocation	-	In Clinical Trials
PREXASERTIB	321	CHEK1	-	-	In Clinical Trials
RABUSERTIB	320	CHEK1	-	-	In Clinical Trials
SCH 900776	320	CHEK1	-	-	In Clinical Trials
PF-477736	320	CHEK1	-	-	In Clinical Trials
TISLELIZUMAB	295	PD-1	-	-	In Clinical Trials
CEMIPLIMAB	294	PD-1	-	-	Approved - Other Tumor Type
GEPTANOLIMAB	294	PD-1	-	-	In Clinical Trials
DOSTARLIMAB	294	PD-1	-	-	Approved - Other Tumor Type
CAMRELIZUMAB	294	PD-1	-	-	In Clinical Trials
ABBV-181	293	PD-1	-	-	In Clinical Trials
REPOTRECTINIB	291	ROS1	ROS1 translocation	-	In Clinical Trials
JQ1	271	BRD4	MYC amplification	-	In Clinical Trials
FADRACICLIB	230	CDK9 CDK2	- -	- -	In Clinical Trials
SNS-032	230	CDK9 CDK2	- -	- -	In Clinical Trials
SELICICLIB	230	CDK9 CDK2	- -	- -	In Clinical Trials
BI 2536	166	PLK1	-	-	In Clinical Trials
VOLASERTIB	166	PLK1	-	-	In Clinical Trials
NMS-P937	166	PLK1	-	-	In Clinical Trials
TAK-960	166	PLK1	-	-	In Clinical Trials
GSK-461364	166	PLK1	-	-	In Clinical Trials
ADAVOSERTIB	138	WEE1	TP53-G266R	-	In Clinical Trials
M3814	135	PRKDC	TP53-G266R	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
CD437	133	RARG	TP53-G266R	-	In Clinical Trials
Barasertib	130	AURKB	TP53-G266R	-	In Clinical Trials
ALISERTIB	104	AURKA	-	-	In Clinical Trials
MLN8054	102	AURKA	-	-	In Clinical Trials
LY3295668	102	AURKA	-	-	In Clinical Trials
ENMD-2076	102	AURKA	-	-	In Clinical Trials
MK-5108	102	AURKA	-	-	In Clinical Trials
TOZASERTIB LACTATE	102	AURKA	-	-	In Clinical Trials
EPRENETAPOPT	90	-	TP53-G266R	-	In Clinical Trials
ANASTROZOLE	89	-	PGR overexpression	-	Approved - This Tumor Type
DASATINIB	85	-	MYC amplification	-	Approved - Other Tumor Type
PEVONEDISTAT	85	-	TP53-G266R	-	In Clinical Trials
ENTOSPLETINIB	84	-	TP53-G266R	-	In Clinical Trials
BEVACIZUMAB	80	-	TP53-G266R	-	Approved - This Tumor Type
BERZOSERTIB	77	ATR	STAG2-A570V	-	In Clinical Trials
NEO2734	74	BRD4	-	-	In Clinical Trials
BMS-986158	74	BRD4	-	-	In Clinical Trials
BIRABRESIB	74	BRD4	-	-	In Clinical Trials
RO6870810	74	BRD4	-	-	In Clinical Trials
AZD5153	74	BRD4	-	-	In Clinical Trials
PELABRESIB	74	BRD4	-	-	In Clinical Trials
CC-90010	74	BRD4	-	-	In Clinical Trials
MOLIBRESIB	74	BRD4	-	-	In Clinical Trials
JNJ-26483327	68	EGFR ERBB2 ERBB4	- - -	- - -	In Clinical Trials
AMG 900	66	-	TP53-G266R	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
COTI-2	66	-	TP53-G266R	-	In Clinical Trials
PK9318	66	-	TP53-G266R	-	In Clinical Trials
PC14586	65	-	TP53-G266R	-	In Clinical Trials
PK11007	65	-	TP53-G266R	-	In Clinical Trials
WITHAFERIN A	65	-	TP53-G266R	-	In Clinical Trials
ZMC1	65	-	TP53-G266R	-	In Clinical Trials
PK7088	65	-	TP53-G266R	-	In Clinical Trials
WITHANONE	65	-	TP53-G266R	-	In Clinical Trials
ATORVASTATIN	65	-	TP53-G266R	-	Approved - Other Tumor Type
SLMP53-2	64	-	TP53-G266R	-	In Clinical Trials
CP31398	64	-	TP53-G266R	-	In Clinical Trials
IBRUTINIB	49	ERBB4	-	-	Approved - Other Tumor Type
TAK-285	24	EGFR ERBB2	ERBB4-T209S	- -	In Clinical Trials
ALLITINIB	23	EGFR ERBB2	- -	- -	In Clinical Trials
PELITINIB	23	EGFR ERBB2	- -	- -	In Clinical Trials
AV-412	23	EGFR ERBB2	- -	- -	In Clinical Trials
CUDC-101	23	EGFR ERBB2	- -	- -	In Clinical Trials
CELECOXIB	10	COX2	-	-	Approved - Other Tumor Type
ENZALUTAMIDE	8	-	-	-	Approved - Other Tumor Type
SACITUZUMAB GOVITECAN	7	-	-	-	Approved - This Tumor Type
CERALASERTIB	5	-	STAG2-A570V	-	In Clinical Trials
ABIRATERONE	4	-	-	-	Approved - Other Tumor Type
TRAMETINIB	4	MAP2K1	PIK3CA-H1047R	-	Approved - Other Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
APALUTAMIDE	3	-	-	-	Approved - Other Tumor Type
ENFORTUMAB VEDOTIN	3	-	-	-	Approved - Other Tumor Type
BLINATUMOMAB	3	-	-	-	Approved - Other Tumor Type
ISATUXIMAB	2	-	-	-	Approved - Other Tumor Type
RIPRETINIB	2	-	-	-	Approved - Other Tumor Type
ZIV-AFLIBERCEPT	2	-	-	-	Approved - Other Tumor Type
RAMUCIRUMAB	2	-	-	-	Approved - Other Tumor Type
TGX221	2	PIK3CB	SETD2-D868G	-	In Clinical Trials
SELINEXOR	2	-	-	-	Approved - Other Tumor Type
DINUTUXIMAB	2	-	-	-	Approved - Other Tumor Type
TILMACOXIB	2	COX2	-	-	In Clinical Trials
AZD6482	2	PIK3CB	SETD2-D868G	-	In Clinical Trials
VISMODEGIB	2	-	-	-	Approved - Other Tumor Type
BORTEZOMIB	2	-	-	-	Approved - Other Tumor Type
CEDIRANIB	2	-	-	-	In Clinical Trials
CILTACABTAGENE AUTOLEUCEL	2	-	-	-	Approved - Other Tumor Type
NS-398	2	COX2	-	-	In Clinical Trials
DARATUMUMAB	2	-	-	-	Approved - Other Tumor Type
LENVATINIB	2	-	-	-	Approved - Other Tumor Type
OBINUTUZUMAB	2	-	-	-	Approved - Other Tumor Type
IMATINIB	2	-	-	-	Approved - Other Tumor Type
PAZOPANIB	1	-	TP53-G266R	-	Approved - Other Tumor Type
CARFILZOMIB	1	-	-	-	Approved - Other Tumor Type
BELINOSTAT	1	-	-	-	Approved - Other Tumor Type
BELANTAMAB MAFODOTIN	1	-	-	-	Approved - Other Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
AZD8186	1	PIK3CB	-	-	In Clinical Trials
VORINOSTAT	1	-	-	-	Approved - Other Tumor Type
SORAFENIB	1	-	-	-	Approved - Other Tumor Type
LENALIDOMIDE	1	-	-	-	Approved - Other Tumor Type
REGORAFENIB	1	-	-	-	Approved - Other Tumor Type
ORTERONEL	1	-	-	-	In Clinical Trials
GSK2636771	1	PIK3CB	-	-	In Clinical Trials
TALIMOGENE LAHERPAREPVEC	1	-	-	-	Approved - Other Tumor Type
TREBANANIB	1	-	-	-	In Clinical Trials
NINTEDANIB	1	-	-	-	Approved - Other Tumor Type
DUVELISIB	1	-	-	-	Approved - Other Tumor Type
VENETOCLAX	1	-	-	-	Approved - Other Tumor Type
Imetelstat	1	-	-	-	In Clinical Trials
SAR260301	1	PIK3CB	-	-	In Clinical Trials
NIROGACESTAT	1	-	-	-	In Clinical Trials
GLASDEGIB	1	-	-	-	Approved - Other Tumor Type
TISOTUMAB VEDOTIN	1	-	-	-	Approved - Other Tumor Type
DENOSUMAB	1	-	-	-	Approved - Other Tumor Type
ACALISIB	1	PIK3CB	-	-	In Clinical Trials
BRENTUXIMAB VEDOTIN	0	-	-	-	Approved - Other Tumor Type
TEBENTAFUSP	0	-	-	-	Approved - Other Tumor Type
SILMITASERTIB	0	-	-	-	In Clinical Trials
SONIDEGIB	0	-	-	PIK3CA-H1047R	Approved - Other Tumor Type
ANLOTINIB	0	-	-	-	In Clinical Trials
DINUTUXIMAB BETA	0	-	-	-	Approved - Other Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
DAROLUTAMIDE	0	-	-	-	Approved - Other Tumor Type
PRACINOSTAT	0	-	-	-	In Clinical Trials
TOFACITINIB	0	-	-	-	Approved - Other Tumor Type
PROPRANOLOL	0	-	-	-	In Clinical Trials
BAVDEGALUTAMIDE	0	-	-	-	In Clinical Trials
ZANUBRUTINIB	0	-	-	-	Approved - Other Tumor Type
Metarrestin	0	-	-	-	In Clinical Trials
NICLOSAMIDE	0	-	-	-	Approved - Other Tumor Type
HER2-BBz-CAR T cells	0	-	-	-	In Clinical Trials
NEO1132	0	-	-	-	In Clinical Trials
NAVITOCLAX	0	-	-	-	In Clinical Trials
ACALABRUTINIB	0	-	-	-	Approved - Other Tumor Type
LUCITANIB	0	-	-	-	In Clinical Trials
AVAPRITINIB	0	-	-	-	Approved - Other Tumor Type
OLARATUMAB	0	-	-	-	Approved - Other Tumor Type
trichostatin A	0	-	-	-	In Clinical Trials
ELTANEXOR	0	-	-	-	In Clinical Trials
NILOTINIB	0	-	-	-	Approved - Other Tumor Type
AXICABTAGENE CILOLEUCEL	0	-	-	-	Approved - Other Tumor Type
AZD4547	0	-	-	-	In Clinical Trials
BICALUTAMIDE	0	-	-	-	Approved - Other Tumor Type
TRILACICLIB	0	-	-	-	Approved - Other Tumor Type
AICAR	0	-	-	-	In Clinical Trials
ENTINOSTAT	0	-	-	-	In Clinical Trials
RUXOLITINIB	0	-	-	-	Approved - Other Tumor Type
FLUVASTATIN	0	-	-	-	Approved - Other Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
MIBG	0	-	-	-	In Clinical Trials
CD30 CAR T-cells	0	-	-	-	In Clinical Trials
RILUZOLE	0	-	-	-	Approved - Other Tumor Type
MIDOSTAURIN	0	-	-	-	Approved - Other Tumor Type
IXAZOMIB	0	-	-	-	Approved - Other Tumor Type
MEDI-573	0	-	-	-	In Clinical Trials
RIGOSERTIB	0	-	-	-	In Clinical Trials
NAXITAMAB	0	-	-	-	Approved - Other Tumor Type
CERDULATINIB	0	-	-	-	In Clinical Trials
AXITINIB	0	-	-	-	Approved - Other Tumor Type
DOVITINIB	0	-	-	-	In Clinical Trials
IPILIMUMAB	-1	-	-	-	Approved - Other Tumor Type
FK866	-2	-	-	-	In Clinical Trials
DABRAFENIB	-14	-	-	STAG2-A570V	Approved - Other Tumor Type
SUNITINIB	-63	-	-	-	Approved - Other Tumor Type
AMG-232	-65	-	-	TP53-G266R	In Clinical Trials
NUTLIN-3A	-66	-	-	TP53-G266R	In Clinical Trials
TALETRECTINIB	-93	ROS1	-	-	In Clinical Trials
R-CHOP group	-101	-	-	TP53-G266R	Approved - Other Tumor Type
EGFR inhibitor	-408	-	-	ROS1 translocation	In Clinical Trials
LORLATINIB	-746	ROS1	ROS1 translocation	PIK3CA-H1047R	Approved - Other Tumor Type
ELACESTRANT	-991	ESR1	ESR1 overexpression	-	In Clinical Trials
FORETINIB	-1070	MET ROS1	ROS1 translocation	- -	In Clinical Trials
CABOZANTINIB	-1074	MET ROS1	ROS1 translocation	- -	Approved - Other Tumor Type
AZD9496	-1130	ESR1	ESR1 overexpression	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
GIREDESTRANT	-1147	ESR1	ESR1 overexpression	-	In Clinical Trials
BRILANESTRANT	-1162	ESR1	ESR1 overexpression	-	In Clinical Trials
AMCENESTRANT	-1188	ESR1	ESR1 overexpression	-	In Clinical Trials
EXEMESTANE	-1192	ESR1	ESR1 overexpression	-	Approved - This Tumor Type
BI-847325	-1290	MAP2K1 AURKA	- -	- -	In Clinical Trials
S49076	-1327	MET AURKB	- -	- -	In Clinical Trials
SELUMETINIB	-1388	MAP2K1	-	-	Approved - Other Tumor Type
GDC-0623	-1391	MAP2K1	-	-	In Clinical Trials
CAPMATINIB	-1391	MET	-	-	Approved - Other Tumor Type
BINIMETINIB	-1391	MAP2K1	-	-	Approved - Other Tumor Type
SITRAVATINIB	-1391	MET	-	-	In Clinical Trials
AMG 208	-1391	MET	-	-	In Clinical Trials
AMG 337	-1391	MET	-	-	In Clinical Trials
E6201	-1391	MAP2K1	-	-	In Clinical Trials
MIRDAMETINIB	-1391	MAP2K1	-	-	In Clinical Trials
TAK-733	-1391	MAP2K1	-	-	In Clinical Trials
TEPOTINIB	-1391	MET	-	-	Approved - Other Tumor Type
MASITINIB	-1391	MET	-	-	In Clinical Trials
U0126	-1391	MAP2K1	-	-	In Clinical Trials
AS703988	-1391	MAP2K1	-	-	In Clinical Trials
CH5126766	-1391	MAP2K1	-	-	In Clinical Trials
MK-2461	-1391	MET	-	-	In Clinical Trials
BMS777607	-1391	MET	-	-	In Clinical Trials
REFAMETINIB	-1391	MAP2K1	-	-	In Clinical Trials
TIVANTINIB	-1391	MET	-	-	In Clinical Trials

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
AZD8330	-1391	MAP2K1	-	-	In Clinical Trials
SAVOLITINIB	-1391	MET	-	-	In Clinical Trials
ONARTUZUMAB	-1391	MET	-	-	In Clinical Trials
GOLVATINIB	-1391	MET	-	-	In Clinical Trials
PF-04217903	-1391	MET	-	-	In Clinical Trials
SAR125844	-1391	MET	-	-	In Clinical Trials
COBIMETINIB	-1391	MAP2K1	-	-	Approved - Other Tumor Type
XL-092	-1391	MET	-	-	In Clinical Trials
WX-554	-1391	MAP2K1	-	-	In Clinical Trials
RILOTUMUMAB	-1391	MET	-	-	In Clinical Trials
SGX523	-1391	MET	-	-	In Clinical Trials
PIMASERTIB	-1391	MAP2K1	-	-	In Clinical Trials
RO4987655	-1391	MAP2K1	-	-	In Clinical Trials
PD98059	-1391	MAP2K1	-	-	In Clinical Trials
EMD 1204831	-1391	MET	-	-	In Clinical Trials
ARRY-300	-1391	MAP2K1	-	-	In Clinical Trials
ALECTINIB	-1392	-	-	PIK3CA-H1047R	Approved - Other Tumor Type
CI-1040	-1395	MAP2K1	-	-	In Clinical Trials
FOLFOX	-1400	-	-	PIK3CA-H1047R	Approved - Other Tumor Type
Anthracycline	-1420	-	-	PIK3CA-H1047R	In Clinical Trials
VEMURAFENIB	-1422	- -	- -	PIK3CA-H1047R STAG2-A570V	Approved - Other Tumor Type
FULVESTRANT	-1726	ESR1	ESR1 overexpression	PIK3CA-H1047R MYC amplification	Approved - This Tumor Type
LETROZOLE	-1784	ESR1	ESR1 overexpression	ERBB2 overexpression ERBB2 amplification	Approved - This Tumor Type
CRIZOTINIB	-2002	MET ROS1	ROS1 translocation	PIK3CA-H1047R ERBB2 overexpression TP53-G266R	Approved - Other Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
BAZEDOXIFENE	-2096	ESR1	-	-	Approved - Other Tumor Type
SRN-927	-2096	ESR1	-	-	In Clinical Trials
SAPITINIB	-2448	EGFR ERBB3	- -	- -	In Clinical Trials
MEHD7945A	-2448	EGFR ERBB3	- -	- -	In Clinical Trials
TAMOXIFEN	-2940	ESR1	ESR1 overexpression	ERBB2 overexpression ERBB2 amplification RB1 gene loss	Approved - This Tumor Type
NECITUMUMAB	-3633	EGFR	-	-	Approved - Other Tumor Type
VANDETANIB	-3633	EGFR	-	-	Approved - Other Tumor Type
BIBX 1382	-3634	EGFR	-	-	In Clinical Trials
BRIGATINIB	-3634	EGFR	-	-	Approved - Other Tumor Type
NIMOTUZUMAB	-3634	EGFR	-	-	In Clinical Trials
IMGATUZUMAB	-3634	EGFR	-	-	In Clinical Trials
SIMOTINIB	-3634	EGFR	-	-	In Clinical Trials
AEE788	-3634	EGFR	-	-	In Clinical Trials
ZALUTUMUMAB	-3634	EGFR	-	-	In Clinical Trials
TESEVATINIB	-3634	EGFR	-	-	In Clinical Trials
XILIERTINIB	-3634	EGFR	-	-	In Clinical Trials
H 447	-3634	EGFR	-	-	In Clinical Trials
PETOSEMTAMAB	-3634	EGFR	-	-	In Clinical Trials
PKI 166	-3634	EGFR	-	-	In Clinical Trials
MATUZUMAB	-3634	EGFR	-	-	In Clinical Trials
GEFITINIB	-3635	EGFR	-	TP53-G266R	Approved - Other Tumor Type
OSIMERTINIB	-4106	EGFR	- -	ROS1 translocation TP53-G266R	Approved - Other Tumor Type
AMIVANTAMAB	-5025	MET EGFR	- -	- -	Approved - Other Tumor Type

Drug	GDS	Matching Targets	Positively Associated Molecular Biomarkers	Negatively Associated Molecular Biomarkers	Category
ERLOTINIB	-5083	EGFR	ERBB4-T209S	PIK3CA-H1047R TP53-G266R	Approved - Other Tumor Type
CETUXIMAB	-5155	EGFR	- - -	ERBB2 amplification PIK3CA-H1047R TP53-G266R	Approved - Other Tumor Type
PANITUMUMAB	-6185	EGFR	- -	PIK3CA-H1047R ERBB2 amplification	Approved - Other Tumor Type

Glossary

Genomate Drug Score (GDS)

The Genomate Drug Score represents each compound's aggregated evidence level (AEL) as defined in Petak I et al. NPJ Precis Oncol. 2021 Jun 23;5(1):59. GDS represents the number, scientific impact and clinical relevance of evidence relations in the system, connecting tumor types, molecular alterations, targets, and drugs. On the first page of the Genomate Report, a selection of the drugs associated with the molecular profile is listed. Drugs are classified according to their GDSs into three categories: in High GDS and Intermediate GDS categories, drugs of the highest GDSs in their respective categories are shown. In Low GDS, drugs with the lowest GDSs are shown.
The full list of drugs is shown in the Additional Therapy Options section.

↑ High Genomate Drug Score (GDS)

This category includes Molecularly Targeted Agents (MTAs) having a high number of positive evidence relations associated with the patient's tumor molecular profile. Higher GDS value was associated with higher effectiveness than other MTAs or standard-of-care chemotherapies in the SHIVA01 study*, indicating a higher likelihood of benefit. High AEL score implies that the MTA targets the most important drivers and associated targets with high aggregated evidence levels, thereby being more likely to control the disease and potentially lead to an extended progression-free survival period.

± Intermediate Genomate Drug Score (GDS)

MTAs with intermediate GDS had moderate effectiveness (statistically on par with standard-of-care chemotherapies) in the SHIVA01 study*. They have a moderate number of positive associations with the patient's tumor molecular profile. The intermediate score indicates that these MTAs have a somewhat positive overall association with the molecular profile, but either the associated drivers are of low evidence, or the association with the drivers and/or targets have low matching, or there are conflicting pieces of evidence, or conflicting associations with the molecular profile, for example, the presence of drivers that confer resistance to the drug. MTAs at this level of evidence can be effective, but the supporting evidence is not as strong as those in the high GDS score category.

↓ Low Genomate Drug Score (GDS)

These MTAs have more negative associations than positive ones with the patient's tumor molecular profile, indicating a lower likelihood of effectiveness, for example, due to the presence of well-evidenced resistance mutations. Statistically, these MTAs had inferior efficacy to standard-of-care chemotherapies in the SHIVA01 study*. The low score suggests that these MTAs are less likely to control the disease and may lead to a shorter progression-free survival period.

Petak, I., Kamal, M., Dirner, A. et al. A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial. npj Precis. Onc. 5, 59 (2021); https://www.nature.com/articles/s41698-021-00191-2.

Genomate Biomarker Score

Genomate Biomarker Score represents the aggregated evidence level (AEL) for each alteration, as described in Petak I et al. NPJ Precis Oncol. 2021 Jun 23;5(1):59. Genomate Biomarker Scores express the importance of the specific alteration in cancer development. It is obtained by weighting and aggregating the scores of scientific evidence underscoring the role, or lack of it, of an alteration in tumorigenesis.

Genomate Target Score

Genomate Target Score represents the aggregated evidence level (AEL) for each drug target as described in Petak I et al. NPJ Precis Oncol. 2021 Jun 23;5(1):59. Genomate Target Scores express the relevance of a specific drug target within the context of the individual tumor molecular profile. It is obtained by weighting and aggregating the scores of scientific evidence underscoring the efficacy, or lack of it, of a drug target in relation to the associated genomic alterations.

Approved Drugs

Drugs approved by the FDA (U.S. Food and Drug Administration) or by the EMA (European Medicines Agency). Drugs Approved in Patient's Tumor Type are drugs that are registered in any indication of the patient's disease. The drug labels are not filtered according to disease stage, previous treatments, biomarker criteria, or any other aspects except for the tumor type. The approval status of the drugs is updated with new software version releases, so recent changes might not be marked in the report.

Molecular Alterations

Point mutations, small indels, gene amplifications, gene fusions, gene loss, tumor mutational burden status, microsatellite instability status, IHC results detected in the patient's tumor by molecular diagnostic test, results of which were provided for the Genomate Analysis.

Target Genes

The efficacy of the inhibition of these gene products is associated with the patient's molecular profile or the patient's tumor type. The strength and nature of this association are expressed by the Genomate Target Scores.

Petak, I., Kamal, M., Dirner, A. et al. A computational method for prioritizing targeted therapies in precision oncology: performance analysis in the SHIVA01 trial. npj Precis. Onc. 5, 59 (2021); https://www.nature.com/articles/s41698-021-00191-2.

Disclaimer

This report was generated by Genomate™, a clinical decision-support AI-based software system for precision oncology. The clinical utility of Genomate™ was assessed by analyzing the clinical data of patients treated in the SHIVA01 targeted therapy basket trial. For more details, see Petak I et al. NPJ Precis Oncol. 2021 Jun 23;5(1):59.
Through its complex algorithms, Genomate™ considers the full complexity of the molecular profile, including the interaction between co-occurring genetic alterations. Genomate™ aggregates, on average 500-1000 pieces of evidence per report, using a series of complex standardized algorithms to prioritize driver genetic alterations, targets, and molecularly targeted agents associated with the individual molecular profile of the patient's tumor, rendering an automatically calculated score, the Genomate Drug Score (GDS). The GDS of a particular molecularly targeted agent is influenced by the aggregated scores of drivers and targets a drug is associated with, as well as the scores of the associations between the treatment and these drivers and targets. The GDS of treatments may change if used in combinations, due to possible synergism at a molecular level. The 2023 version of the system uses evidence-based 34,000+ driver-target-compound interactions in its computational model.

This report can be used and clinically interpreted only by physicians or other qualified healthcare professionals. It provides information about the GDS scores of drivers, targets, and treatment options associated with the tumor type and molecular profile provided as input for this analysis. The output scores depend on the type of molecular diagnostic assay used for the analysis. This report is not medical advice and is not intended to be relied upon as the basis for any prevention, diagnosis, treatment, or other clinical decision-making. Healthcare professionals may consider or disregard the information to choose between treatment options provided by this report. Healthcare professionals are encouraged to independently review the basis for the information contained in this report and must use their own independent judgment in making any clinical decision regarding an individual patient. The drugs indicated in this report may or may not be registered and/or reimbursed in the specific tumor type in the country in which this report is used. The scores indicated in this report do not guarantee efficacy or lack of efficacy of any treatment. Genomate Health Inc. does not take responsibility for the content or accuracy of this report or any referenced pieces of evidence nor for any decision made by any healthcare professional based on the information contained herein.

Genomate™ is a clinical decision support software, as described in Section 520(o) of the Federal Food, Drug, and Cosmetic Act (FDCA). None of the statements contained herein have been evaluated by the U.S. Food and Drug Administration. Genomate™ is not intended to diagnose, treat, cure, prevent, or mitigate any condition and is not a "device" as such term is defined in Section 201(h) of the FDCA. The system is a registered CE-marked CLASS 1 medical device in the European Union.

For more information contact us at support@genomate.health

Genomate®